课题基金 / 基金详情

Molecular mechanisms of isotype switch recombination.

Molecular mechanisms of isotype switch recombination.
同型转换重组的分子机制。
批准号:
11470083
负责人:
TAKATSU Kiyoshi
金额:
$9.22万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B).
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000

项目摘要

项目成果

TAKATSU Kiyoshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mouse B cells express CD38 whose ligation by anti-CD38 antibody induces their proliferation and protection from apoptosis. We previously showed that stimulation of mouse splenic B cells with interleukin 5 (IL-5) together with CS/2, an anti-mouse CD38 monoclonal antibody, induces production of IgG1 and IgM.Here we examined the role of IL-5 and CS/2 in the expression of germline γ1 transcripts and the generation of reciprocal products forming DNA circles as by products of μ-γ1 switch recombination. By itself, CS/2 induced significant expression of germline γ1 transcripts in splenic naive B cells, whereas IL-5 neither induced nor enhanced germline γ1 expression. Increased cellular content of reciprocal product, which is characteristic of μ-γ1 recombination, was not observed after culturing B cells with CS/2, but increased reciprocal product along with high levels of IgG1 secretion was found when B cells were cultured with CS/2 plus IL-5. Although IL-4 did not, by itself, induce μ-γ1 recom … More bination in B cells stimulated with CS/2, in conjunction with CS/2 plus IL-5, IL-4 dramatically enhanced sterile γ1 transcription and IgG1 production. These results demonstrate that CD38 ligation induces only germline γ1 transcription and that IL-5 promotes both μ-γ1 switch recombination and IgG1 secretion in an IL-4 independent manner.Although some post-receptor signaling events of IL-5 in activated B cells have been characterized, the involvement of the Janus kinase/signal transducer and activator (Jak/Stat) pathway in IL-5 signaling has not been thoroughly evaluated. In this study, we examined whether IL-5 activates the Jak/Stat pathway in CD38-activated mouse splenic B cells. Both Stat5a and Stat5b were activated by IL-5 stimulation. The role of Stat5a and Stat5b in IL-5-induced μ-γ1 switch recombination and IgG1 production were documented, as IL-5 did not act on CD38-stimnulated splenic B cells of Stat5a^<-/-> and Stat5b^<-/-> mouse. Expression levels of germline γ1 transcripts to CD38 and of activation-induced cytidine deaminase (AID) in Stat5a^<-/-> and Stat5b^<-/-> B cells upon IL-5 stimulation were comparable to these of wild type B cells. Thus, both Stat5a and Stat5b are essential for at IL-5-dependent μ-γ1 switch recombination, and their targets may not be g1 and AID genes. The impaired μ-γ1 switch recombination by Stat5b^<-/-> B cells, but not by Stat5a^<-/-> B cells, were rescued in part by IL-4, as the addition of IL-4 to the culture of CD38- and IL-5-stimulated B cells did induce μ-γ1 switch recombination leading to significant IgG1 production. Our data support the notion that Stat5a and Stat5b are not redundant, but rather are at least partially distinctive in their function on B cell differentiation. Analysis of cell division cycle number of B cells, examined by using 5-, 6-carboxyfluorescein diacetate, succinimidyl ester (CFSE), revealed that μ-γ1 switch recombination and surface IgG1-positive cells were observed after 5 to 6 division cycles upon CS/2 and IL-5. Stat5a^<-/-> and stat5b^<-/-> B cells showed 5 to 6 cell division cycles, but they could express neither μ-γ1 switching nor surface IgG1. Less
期刊论文(58)
专著(0)
科研奖励(0)
会议论文
Kouro, T., K.Nagata, S.Takaki, K.Takatsu, et al.: "Bruton's tyrosine kinase (Btk) is required for CD75b-mediated differentiation signal of pro-B to pre-B transition."Int.Immunol.. (In press). (2001)
Kouro, T.、K.Nagata、S.Takaki、K.Takatsu 等人:“Bruton 酪氨酸激酶 (Btk) 是 CD75b 介导的原 B 向前 B 转变的分化信号所必需的。”Int.Immunol
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Mizoguchi, C., S.Uehara, S.Akira, and K.Takatsu.: "Interleukin-5 Induces IgG1 Isotype Switch Recombination in mouse CD38-Activated slgD-Positive B Lymphocytes."J.Immunol.. 162. 2812-2819 (1999)
Mizoguchi, C.、S.Uehara、S.Akira 和 K.Takatsu.:“Interleukin-5 在小鼠 CD38 激活的 slgD 阳性 B 淋巴细胞中诱导 IgG1 同型转换重组。”J.Immunol.. 162. 2812-2819
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kikuchi, Y., M.Hirano, M.Seto, and K.Takatsu.: "Identification and characterization of a molecule, BAM11, that associates with the PH-domain of mouse Btk."Int.Immunol.. 12. 1397-1408 (2000)
Kikuchi, Y.、M.Hirano、M.Seto 和 K.Takatsu.:“与小鼠 Btk 的 PH 域相关的分子 BAM11 的识别和表征。”Int.Immunol.. 12. 1397-
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takatsu K.,et al.: "IgG1 production by IgD+ splenic B cells and peritoneal B-1 cells in response to IL-5 and CD38 ligation"Int.Immunol.. 11. 915-923 (1999)
Takatsu K.等人:“IgD 脾 B 细胞和腹膜 B-1 细胞响应 IL-5 和 CD38 连接而产生 IgG1”Int.Immunol.. 11. 915-923 (1999)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
25
    Analysis of innate IL-5 producing cells in immune responses and chronic inflammation
    • 批准号:
      24390119
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2012
    • 负责人:
      TAKATSU Kiyoshi
    • 依托单位:
    Spatiotemporal control of allergy and non-infectious inflammation and their regulation by natural products
    Roles of cytokines and TLRs in lymphocyte activation and differentiation
    • 批准号:
      20390141
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.73万
    • 财政年份:
      2008
    • 负责人:
      TAKATSU Kiyoshi
    • 依托单位:
    Enhancement of Th1 and antitumor immunity by Ag85B and Peptide-25.
    国内基金
    海外基金
    力学刺激调控巨噬细胞CD38/NAD+SIRT1轴促进肩袖损伤修复术后腱骨愈合的机制与验证研究
    • 批准号:
      JCZRLH202602006
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    胆管癌中CD38介导的NAD+耗竭导致SIRT1失活并促进FXR高乙酰化修饰的代谢机制研究
    ABCA1/CD38/NAD+通路诱导巨噬细胞衰老促进子宫内膜异位症进展的机制研究
    • 批准号:
      2026JJ80446
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      曾文
    • 依托单位:
    基于虚拟筛选的CD38小分子抑制剂T67751在鼻咽癌中的作用及其机制研究
    • 批准号:
      2026JJ81933
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      唐婧琼
    • 依托单位: